news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

the list of securities eligible for the hong kong stock connect has been adjusted, effective from september 10.

alibaba-w officially included in hong kong stock connect

on september 9, the shanghai and shenzhen stock exchanges issued a notice stating that due to the regular adjustment of constituent stocks of the hang seng composite large cap index, mid cap index, and small cap index, according to relevant regulations, the list of securities eligible for the hong kong stock connect will be adjusted and will take effect from september 10, 2024.

according to the adjustment list, 33 stocks including alibaba-w, hang lung group, ka wah international, cofco packaging, qz group, zhixing automotive technology, sinopec refining and chemical engineering, dekang agriculture and animal husbandry, auto street, sino-us jiahe, yisou technology, chabaidao, maifushi, wanwu cloud, jiangnan buyi, china ship leasing, laopu gold, sunshine insurance, sf express, and cloud music were transferred in.

33 stocks including zhongshouyou, xiabu xiabu, pudat technology, shimao group, xuhui holdings group, feifan lingyue, zhuguang holdings, yidianyun, sino-ocean group, agile group, bohai bank, dingdang health, and zhiyun health were removed.

that is to say, starting from september 10, southbound funds will be able to purchase stocks such as alibaba-w through the hong kong stock connect.

earlier, alibaba-w announced that it had officially completed its dual primary listing in hong kong, becoming a company with dual primary listings on the hong kong stock exchange and the new york stock exchange. the company's common shares listed on the hong kong stock exchange and its american depositary shares listed on the new york stock exchange continue to be convertible.

overseas investment institutions are optimistic about the prospect of alibaba-w being included in the hong kong stock connect. morgan stanley's research report said that in the long run, the proportion of southbound funds holding shares may stabilize at more than 10%; goldman sachs' research report predicts that southbound funds will bring potential capital inflows of us$15 billion to us$16 billion to alibaba-w.

my country's first monkeypox vaccine approved for clinical trials

according to the china national biotec group's wechat public account, on september 9, the mva strain monkeypox live attenuated vaccine independently developed by sinopharm group china national biotec group's shanghai institute of biological products received a clinical trial notification issued by the national medical products administration. this is the first monkeypox vaccine approved for clinical use in my country, and is expected to play an important role in the prevention and control of diseases caused by the monkeypox virus in my country.

on august 14, the world health organization announced that the monkeypox outbreak constituted a public health emergency of international concern. on august 22, the thai ministry of public health held a press conference to confirm the first case of the monkeypox ib variant in the country. on september 6, the africa centers for disease control and prevention and the world health organization announced the launch of a joint plan to respond to the monkeypox outbreak on the african continent.

13 monkeypox concept stocks achieved good performance in the first half of the year

according to securities times databao, there are 13 monkeypox concept stocks whose semi-annual net profits exceeded 100 million yuan and whose year-on-year growth rates were among the highest.in terms of net profit scale, the net profit scale of xinye industry, sinopharm modern pharmaceutical, enhua pharmaceutical, and antu biological exceeded 500 million yuan, which were 903 million yuan, 718 million yuan, 629 million yuan, and 620 million yuan, respectively.

previously, the clinical trial application for the replication-defective monkeypox vaccine independently developed by the beijing institute of biological products of sinopharm group china national biotec group was officially accepted by the drug review center (cde) of the national medical products administration.

in 2022, antu biotech's monkeypox virus nucleic acid detection kit (pcr-fluorescent probe method) was approved by the eu ce. the company said that in the current large-scale outbreak of monkeypox, the company has promptly communicated with relevant epidemic countries about their demand for monkeypox detection products and closely followed the development of global public health events.

from the perspective of year-on-year changes in net profit, the net profits of innotech and sinopharm modern pharmaceuticals doubled year-on-year, with increases of 166.45% and 108.29% respectively; the net profit growth of aotai biopharm, shengxiang biopharm and chuangyuan technology also exceeded 60%.

innotech recently stated on an interactive platform that the company has monkeypox virus antigens and monkeypox virus nucleic acid detection kits (ce access qualifications), but the related products have not yet contributed to its performance; aotai biotech has currently obtained the eu ce certification for monkeypox products and can be sold in eu countries and countries that recognize the eu ce certification. the company will continue to closely monitor the development of monkeypox-related epidemics in overseas markets.

shengxiang bio said that its monkeypox virus nucleic acid detection reagent was successfully selected into the recommended list of monkeypox molecular detection products of the africa centers for disease control and prevention, becoming the first batch of recommended detection reagents.